Introduction {#s1}
============

The liver performs and regulates numerous physiological functions and has the ability to regenerate. Parenchymal cells or hepatocytes constitute \~80% of the liver tissue and execute most of the physiological functions of this organ. The balance of the liver consists of non-parenchymal endothelial, stellate, and Kupffer cells as well as lymphocytes ([@B43]). Successful recovery after partial hepatectomy (PH) depends mainly on rapid residual liver regeneration and liver function recovery. However, few clinically available drugs significantly enhance hepatocyte proliferation or liver regeneration. Therefore, the quest for new drugs or therapeutic targets that can improve liver regeneration is of great theoretical and practical importance.

Several animal models have been designed to evaluate liver regeneration. In 1931, Higgins and Anderson proposed a rat model of 2/3 hepatectomy ([@B37]). It continues to be popular to this day as it involves the excision of intact liver lobes and does not damage the residual liver. In contrast, other models using toxicants such as carbon tetrachloride to induce injury to the residual liver ([@B32]). Though the excised lobes never regenerate, the residual liver tissue restores the original liver mass within \~1 week after surgery ([@B43]). The PH liver regeneration model is used to synchronize and evaluate cell cycle events and signal transduction *in vivo* ([@B7]). Certain *in vitro* methods also synchronize mammalian cell cultures and are used to study regulatory mechanisms of cell cycle progression and cell proliferation. These include serum starvation/deprivation, chemically-induced cell cycle arrest, mitotic shake-off, counterflow centrifugal elutriation, and newer live cell methods. Each of these methods has inherent disadvantages. Nevertheless, serum starvation is simple, reversible, reliable, and generally applicable to mammalian cells ([@B15]) including hepatocytes.

Liver regeneration is extremely complex and involves multiple factors and pathways. Parenchymal and non-parenchymal liver cells proliferate to replace lost hepatic tissue. However, hepatocytes proliferate first ([@B34]). Liver regeneration approximately entails the priming phase (early period after PH; quiescent hepatocytes transition from G0 to G1), the proliferation phase (progression phase; DNA synthesis and hepatocyte proliferation), and the termination phase (hepatocyte proliferation stops as soon as the liver mass is restored) ([@B8]; [@B42]). The earliest signals initiating the regenerative response remain to be elucidated. However, it is known that IL-6 (interleukin-6) and TNF-α (tumor necrosis factor-α) participate in the events that transform hepatocytes from G0 to G1 in the priming phase and this process is mediated by the NF-κB, JAk/STAT, and MAPK signaling pathways ([@B43]; [@B34]; [@B32]; [@B42]). Complete mitogens and auxiliary mitogens are involved in the proliferation phase. The former activates secondary or delayed gene responses, stimulate DNA replication, and induce hepatocyte proliferation *via* the JAk/STAT, PI3K/AKT, mTOR, ERK, and MAPK signaling pathways. Complete mitogens include TGF-α (transforming growth factor-α), HGF (hepatocyte growth factor), EGF (epidermal growth factor), and EGFR (epidermal growth factor receptor) ([@B43]). The latter may partially contribute to regeneration by accelerating or magnifying the effects of complete mitogens even though they are not mitogenic in hepatocytes. Auxiliary mitogens include VEGF (vascular endothelial growth factor), IGF (insulin-like growth factor), Bas (bile acids), NE (norepinephrine), and estrogen ([@B42]). The mechanisms of the termination phase are poorly understood. TGF-β1 (transforming growth factor-β1) is the best known antiproliferative factor ([@B42]). Despite extensive investigation, the exact mechanisms of liver regeneration have not yet been clarified.

Certain animal products have been used in traditional Chinese medicine (TCM). The ancient Chinese science of disease treatment has been advocated for thousands of years. *Periplaneta americana* (PA), the American cockroach, has a long history of application for the treatment of various injuries ([@B2]; [@B55]). Over the past few years, physiological and pharmacological studies have demonstrated that TCM powder and extracts of *Periplaneta americana* (PAEs) ([@B51]) have tissue repair ([@B48]; [@B19]; [@B55]), antitumor ([@B28]; [@B53]), antibacterial ([@B3]; [@B1]), antiviral ([@B18]), antifungal ([@B50]), antifibrotic ([@B20]), antiosteoporotic ([@B11]), cardiomyocyte-protecting ([@B22]), and immunity-enhancing ([@B51]) efficacy. Animal medicines have complex ingredients and it is difficult to isolate and identify effective components. Many researchers are actively engaged in the analysis and identification of ingredients of PAEs and have made some progresses. It has been reported that ([@B30]; [@B24]) PAEs contain polysaccharides, peptides, nucleosides, polyols, steroids, terpenes, alkaloids, flavonoids, and isocoumarins, and the effective constituents of the extracts may include polysaccharides, peptides, nucleosides. However, PAEs have not been fully explored in clinical applications as their active constituents have not been adequately purified and their molecular mechanisms are not fully understood. At present, only a few representative clinical PAEs prescriptions such as "Kangfuxin solution", "Xinmailong injection", "Ganlong capsule" among others are used mainly for the treatment of cutaneous lesions ([@B23]), chronic heart failure ([@B26]), alimentary canal diseases ([@B21]), and chronic hepatitis B ([@B18]). PAEs stimulate healing and inhibit hepatic fibrosis progression. However, it remained uncertain whether PAEs would promote liver regeneration as effectively as skin regeneration. Here, we used a mouse liver regeneration model after 70% PH and a hepatocyte culture to determine the beneficial effects of PAEs in liver regeneration and establish their modes of action.

Materials and Methods {#s2}
=====================

Preparation of *Periplaneta americana* Extracts (PAEs) {#s2_1}
------------------------------------------------------

The original PAEs extractum was supplied by Tengchong Pharmaceutical Co. Ltd., Baoshan, Yunnan, China. The extraction protocol of PEAs followed the patent ([@B18]) involving Ganlong capsule, a medicine for the treatment of chronic hepatitis B clinically in China. The main ingredients are sticky sugar amino acid. Briefly, dried adult *Periplaneta americana* was coarsely crushed and the powder was soaked in 95% ethanol (1:4 w/v) for 24 h and extracted by heat reflux extraction at 80°C for 8 h. After oil-water separation, the aqueous phase was filtered and evaporated under reduced pressure down to the original PAEs extractum with ≤ 15% moisture content. This condensate was stored at -20°C until subsequent use. For intragastric administration or cell culture preparation, the material was diluted in 0.9% (w/v) saline or double-distilled water, respectively.

HPLC Analysis {#s2_2}
-------------

Chromatographic analysis was performed on a Waters E2695 series HPLC system (Waters, MA, USA) equipped with an ultraviolet detector 2998, using an Agilent C18 SB-AQ (4.6mm×150mm, 5μm) at a column temperature of 25°C. The flow rate and injection volume were 1 ml/min and 20 µl, respectively. The methanol--water (2:98) system was employed as the mobile phase for quantitative determination of multiple standard compounds, i.e., cytosine, uracil, cytidine, uridine, inosine, and guanosine. All these standard compounds were dissolved together by 3% methanol to form a mixed standard solution (10 μg/ml). The optimized detection wavelength was 254 nm.

The inosine standard compound (C14328000) was purchased from Dr. Ehrenstorfe Co., LTD, Germany. The other standard compounds, cytosine (CDAA-281383), uracil (CDAA-28071620), cytidine (CDAA-281384), uridine (CDAA-280717), and guanosine (CDAA-280791), were purchased from ANPEL Laboratory Technologies Co., LTD, Shanghai.

Cell Culture {#s2_3}
------------

The normal hepatocyte cell line L02 was obtained from the Tumor Institute of the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. The L02 cells were cultured in Gibco RPMI 1640 Medium without HEPES and supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, MA, USA), 100 U/ml penicillin, and 100 g/ml streptomycin (Invitrogen, Carlsbad, CA, USA) in 5% CO~2~ at 37°C.

Cell Counting Kit-8 (CCK-8) Assay {#s2_4}
---------------------------------

L02 cell proliferation was measured with a CCK-8 kit (Dojindo Laboratories, Kumamoto, Japan). Briefly, cells in the logarithmic growth phase were seeded in 96-well plates at a density of 5×10^3^/well. Each well contained 100 μl culture medium. After 24 h, the cells were incubated in 100 μl culture medium without FBS for 24 h and divided into the serum-starved control group (NC) and the serum starvation + 0.1, 0.5, 1, 25, or 50 mg/ml PAEs groups. After 24, 48, and 72 h, the CCK-8 kit reagents were added to the culture plates in the dark. The cells were incubated under 5% CO~2~ at 37 °C for 40 min. The absorbances were read at 450 nm in an automated plate reader (BioTek). Each experiment was repeated at least in triplicate. Based on the instructions of the CCK-8 kit, the cell proliferation ratio was calculated as follows:
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where A~PAEs~, A~c~, and A~b~ represent the average absorbances of the PAEs group, the control group, and the blank (culture medium without FBS), respectively.

70% Partial Hepatectomy (PH) of C57 Mice {#s2_5}
----------------------------------------

The present study was approved by the Medical Ethics Committee of Kunming Medical University (Kunming, Yunnan Province, China). All experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Utilization Committee.

Healthy 8--14-week male C57 mice weighing 20--24 g were obtained from the Experimental Animal Center of Kunming Medical University. All experimental mice were maintained under standard general anesthesia with intraperitoneal (IP) 3% (v/v) chloral hydrate. The dosage was 1.2 ml/100 g BW. A midline laparotomy was performed and the left lateral and left and right median lobes were ligated and resected. Here, 70% of the mouse liver was surgically removed under sterile conditions ([@B37]). The mortality rate was \< 10%. The main cause of death was bleeding caused by ligation line falling off after 70% PH.

PAEs Administration {#s2_6}
-------------------

To evaluate the effect of PAEs on liver regeneration, male C57 mice were randomly divided into the nonspecific control (NC), normal saline (NS), and low- and high-dose PAEs groups (n = 10 per group).

The PAEs oral dose of adult was no more than 18 g/d in the patent ([@B18]) involving Ganlong capsule, a medicine for the treatment of chronic hepatitis B clinically in China. According to the body surface area (BSA) normalization method, a human equivalent dose (HED) was calculated as follows ([@B38]):
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where the K~m~ factor is 3 for a mouse and 37 for a human. The dose of mice was no more than about 3.7 g/kg/d because oral dose of 60 kg adult was no more than 18 g/d. In the present liver regeneration experiment and in reference to previous studies by others ([@B52]; [@B25]; [@B19]; [@B4]; [@B41]), gavage administration was adopted, in which low- and high-dose PAEs groups were set as PAEs400 (400 mg/kg/d) and PAEs800 (800 mg/kg/d), respectively.

By gavage, the NS mice were administered with normal saline and the PAEs mice were administered with 400 or 800 mg/kg/d for 10 days. At 2 h after the 10th gavage, 70% PH was performed on the NS and PAEs mice. At 48 h after 70% PH, all mice were euthanized by CO~2~ inhalation. Liver tissue samples of all mice including the NC were collected immediately.

Hepatic Regeneration Rate (HRR) Measurement {#s2_7}
-------------------------------------------

After 70% PH, the hepatic regeneration rate (HRR) of the residual liver including the right and caudate lobes was calculated as follows:
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where W~a~ is the calculated initial weight of the whole mouse liver at the start of the 70% PH, and W~b~ and W~c~ are the actual weights of the surgically excised liver tissue and the residual liver tissue at the time of death, respectively. This original weight was calculated as a fixed proportion of the liver weight according to [@B37] and [@B33].

Immunohistochemical (IHC) Staining {#s2_8}
----------------------------------

The right lobe was split into two parts. One section was immediately frozen in liquid nitrogen for later sequencing while the other part was fixed in 10% (v/v) neutral formaldehyde for immunohistochemical (IHC) staining. The segments were fixed overnight, embedded in paraffin, and cut into 4-µm-thick sections (Leica RM2235). Hepatocyte proliferation was estimated by IHC staining for the nuclear antigen Ki-67. This antigen is preferentially expressed during all active cell cycle phases (G1, S, G2, and M) but not in G0 ([@B39]). Anti-Ki-67 Rabbit pAb (WL01384a) was provided by Wanleibio Co. Ltd., Shenyang, China. Immunohistochemical staining was performed using the following protocol included with the kit: primary antibody: 1:100, 4°C, overnight; secondary antibody-biotin: 1:150, 37°C, 1 h; and streptavidin-HRP: 1:200, 37°C, 30 min. The Ki-67-positive hepatocytes (N~P~) and the total hepatocytes (N~T~) were counted in random fields at ×400 magnification. The positive rate (%) of Ki-67 expression was used to enumerate the proliferating hepatocytes in the IHC staining sections and was calculated as follows:
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RNA Sample Preparation, cDNA Library Preparation, and Illumina Sequencing {#s2_9}
-------------------------------------------------------------------------

Nine samples per group were randomly selected. Three samples were randomly mixed and three mixed samples were obtained per group. Total RNA was extracted from each mixed sample with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Twelve DGE libraries (NC, NS, PAEs400, and PAEs800) were processed in an Illumina gene expression sample prep kit (Illumina, San Diego, CA, USA). After cDNA library quality and quantity control, Illumina sequencing was performed in an Illumina HiSeq 2000 (Mus_musculus) at the Beijing Genomics Institute (BGI), Shenzhen, China). The SRA data have been uploaded to NCBI (BioProject: PRJNA635249).

Mapping DEGs to the Mus_Musculus Genome {#s2_10}
---------------------------------------

Raw reads were prepared as follows to create clean reads ([@B5]). Raw reads with adapters and unknown bases (\>5%) were removed. Low-quality reads with quality values \< 10 for \>20% of their bases were filtered out. Clean high-quality tags were mapped to the reference genome with HISAT ([@B12]) and to the reference sequences with Bowtie2 ([@B16]). Based on the mapping results, the RSEM analysis ([@B17]) was executed to quantify the gene expression level and obtain a read count of each gene in each sample. The gene expression levels were calculated by the fragments per kilobase per million reads (FPKM) method ([@B36]).

Functional Analysis of Differentially Expressed Genes (DEGs) {#s2_11}
------------------------------------------------------------

A differential expression analysis between the treatment and control was implemented using a rigorous algorithm. The threshold *P*-value was determined by the false discovery rate (FDR) method in multiple tests ([@B45]). FDR \< 0.001 and absolute value of the log2 ratio ≥ 1 were set as the detection thresholds for genes with significant differential expression. To identify significantly enriched terms, the Mus_musculus (mm10) genome was used as the background to identify GO terms enriched within the DEG dataset *via* a hypergeometric test using a corrected *P*-value (≤ 0.05) as a threshold. A Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed to identify significantly enriched pathways within the DEG datasets. It was compared with the genome database *via* a hypergeometric test using a corrected *P*-value (≤ 0.05) as a threshold.

Data and Statistical Analysis {#s2_12}
-----------------------------

The data were compiled in a spreadsheet in MS Office Excel 2010. Statistical analyses were performed by running *t*-tests on independent samples to identify significant differences. *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

HPLC Quantitative Analysis {#s3_1}
--------------------------

The amounts of six physiological small molecules, i.e., cytosine, uracil, cytidine, uridine, inosine, and guanosine, in PAEs were determined by HPLC. These nucleosides and nucleobases were deemed to be the potential active components in PAEs in the study of intestinal barrier improvement and anti-inflammation effects ([@B31]). As shown in [**Figure S1A**](#SF1){ref-type="supplementary-material"}, these six compounds in mixed standard substances were analyzed, with a satisfied degree of separation and methodological investigation being obtained.

[**Figures S1B, C**](#SF1){ref-type="supplementary-material"} provide clear evidence that the concentrations of these six compounds in PAEs sample could be determined. Accordingly, based on the external standard method, the amounts of these six compounds, i.e., cytosine, uracil, cytidine, uridine, inosine, and guanosine, in PAEs were calculated and the results were 5.91, 6.12, 7.63, 5.97, 3.26, and 1.89 mg/g, respectively. In addition, two unknown substances were found in our study.

Hepatocyte Proliferation *In Vitro* and *In Vivo* {#s3_2}
-------------------------------------------------

*In vitro*, PAEs at low dose (1 mg/ml) was found to accelerate moderate L02 cell (in Gibco RPMI 1640 Medium without HEPES and supplemented with 10% FBS) proliferation. On the other hand, virtually all cells were killed by PAEs at high doses (25 or 50mg/ml). The result was submitted as supplementary material ([**Figure S2**](#SF2){ref-type="supplementary-material"}). The CCK-8 assay showed that different PAEs concentrations (0.1, 0.5, or 1 mg/ml) accelerated L02 cell proliferation under serum starvation conditions ([**Figures 1A, B**](#f1){ref-type="fig"}).

![PAEs efficacy in hepatocyte proliferation both *in vitro* and *in vivo* relative to control. **(A)** Representative images of CCK-8 color reactions in 96-well plates at 48 and 72 h after treatment with different PAEs concentrations. **(B)** Differences in L02 cell proliferation ratios between PAEs treatment group (0.5 mg/ml) and NC group were significant at 48 and 72 h according to Student's *t*-test (\**P* \< 0.05). **(C)** Ki-67 expression levels in residual liver cell nuclei and cytoplasm at 48 h after 70% PH. **(E)** Representative images of residual liver at 48 h after 70% PH. Each group included nine mice. **(D, F)** Differences between PAEs and NS groups were significant according to Student's *t*-test (\**P* \< 0.05; \*\**P* \< 0.01).](fphar-11-01174-g001){#f1}

According to the report of [@B46], abnormal manifestations of the test animals were not observed during the acute toxicity experiment of PAEs. The estimated LD50 was \>2000 mg/kg PAEs in normal ICR mice. According to the report of [@B54], LD50 was \> 10 g/kg TCM powder of *Periplaneta americana* in normal female and male KM mice, and the toxicity grade of *Periplaneta Americana* was practically non-toxic. In our study, abnormal manifestations were not observed in C57 mice who were administered PAEs with 400 or 800 mg/kg. By immunohistochemical staining, Ki-67 was localized in the hepatocyte nuclei of the PAEs800 group. All postoperative groups presented with higher Ki-67 expression than the NC group ([**Figure 1C**](#f1){ref-type="fig"}). The PAEs800 group had a significantly higher Ki-67 expression than that in the NS (*P* \< 0.05) and PAEs400 (*P* \< 0.01) groups 48 h after 70% PH ([**Figure 1D**](#f1){ref-type="fig"}).

Hepatic Regeneration Rate (HRR) {#s3_3}
-------------------------------

The HRR was significantly higher in the PAEs groups than the NS group 48 h after 70% PH (*P* \< 0.05 or *P* \< 0.01). However, the difference in HRR between the PAEs400 and PAEs800 groups ([**Figures 1E, F**](#f1){ref-type="fig"}) was not statistically significant (*P* \> 0.05).

Quantitative Identification of Differentially Expressed Genes (DEGs) 48 h After 70% PH {#s3_4}
--------------------------------------------------------------------------------------

Analysis of the gene expression spectrum detected 11,986 transcripts including 9,266 coding and 2,720 noncoding transcripts. The expression levels of various genes increased or decreased by ≥ 2× (q-value \< 0.001) at 48 h after 70% PH ([**Figure 2A**](#f2){ref-type="fig"}). The PAEs groups presented with significantly fewer DEGs but more downregulated genes than the NS group.

![Quantitative identification of differentially expressed genes (DEGs) 48 h after 70% PH. **(A)** Number of DEGs increased or decreased by ≥ 2× (q-value \< 0.001) in various comparison groups. **(B)** Venn diagram of DEGs between PAEs400/NS and PAEs800/NS. **(C)** Numbers of known DEGs in various elements of Venn diagram.](fphar-11-01174-g002){#f2}

A Venn diagram analysis identified 1,182 DEGs that were commonly expressed among the PAEs and NS groups. Moreover, 408 and 1,077 DEGs were specifically expressed in the PAEs400 and PAEs800 groups, respectively ([**Figure 2B**](#f2){ref-type="fig"}). However, as we focused on the possible effects of the PAEs after 70% PH, we concentrated on the intersection of the 1,182 DEGs. A sequence analysis showed 1,092 reported and 90 unreported genes at the intersection. Of the former, 1,057 were downregulated and only 35 were upregulated in the PAEs400 group while 1,055 reported genes were downregulated and only 37 reported genes were upregulated in the PAEs800 group ([**Figure 2C**](#f2){ref-type="fig"}).

Bioinformatics Analysis of Differentially Expressed Genes (DEGs) {#s3_5}
----------------------------------------------------------------

Gene Ontology (GO) was used to annotate and enrich the DEGs and a Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was used to annotate, enrich, and analyze the signaling pathways. The KEGG pathway analysis functionally classified the 1,092 reported genes expressed in both the PAEs400 and PAEs800 treatment groups. They were categorized by the online BGI according to cellular processes, environmental information processing, genetic information processing, human diseases, metabolism, and organismal systems. [**Figure 3A**](#f3){ref-type="fig"} shows that 153 known genes were separated into the cellular process category. Except for Pdgfrl (kinase insert domain protein receptor), the expression levels of 152 elements in the NS and PAEs groups were significantly higher than those of the NC group. However, the PAEs groups displayed intermediate expression levels. To facilitate the visualization and interpretation of gene expression from these data, we used GeneMaths LOG10(FPKM+1) to rank the DEGs according to their expression patterns and display them in concise and intelligible graphical format ([**Figure 3B**](#f3){ref-type="fig"}). A KEGG pathway enrichment analysis identified the enriched pathways by a two-tailed Fisher's exact test and assessed the enrichment of the 153 DEGs against all identified elements. Enrichment level 2 was restricted to "Cell Growth and Death" and "Signal Transduction" ([**Figure 3C**](#f3){ref-type="fig"}). Pathways with corrected *P*-values ≤ 0.05 were considered statistically significant. The KEGG pathway enrichment analysis indicated that 81 DEGs participated in the cell cycle, apoptosis, and necroptosis processes and/or were involved in the signaling pathways related to cell growth or death (PI3K-Akt, MAPK, Apelin, Wnt, FoxO, mTOR, Ras, VEGF, ErbB, Hippo, and AMPK) ([**Figures 3D, E**](#f3){ref-type="fig"}, [**Table 1**](#T1){ref-type="table"}). Of the 81 DEGs, 34 participated in the liver regeneration process *via* ≥ 2 signaling pathways. Akt3 was implicated in all of the aforementioned signaling pathways except for Wnt and Hippo.

![KEGG analysis of DEGs. **(A)** Annotation and classification by KEGG analysis. **(B)** Expression of 153 DEGs in the "Cellular Processes" category. **(C)** Top 20 pathways. Enrichment of 153 DEGs by KEGG pathway enrichment analysis against all identified elements. Level 2 restricted to "Cell Growth and Death" and "Signal Transduction". Among them, 26 DEGs enriched in PI3K-AKT signaling pathway, and 21 in MAPK signaling pathway. Only seven DEGs enriched in VEGF signaling pathway, but rich ratio was the highest. This analysis result indicated an extremely complex molecular mechanism in the process by which PEAs can promote liver regeneration. **(D)** DEG expression levels in pathways. Legend shown in [**Table 1**](#T1){ref-type="table"}. **(E)** PAEs accelerate hepatocyte proliferation and promote liver regeneration *via* complex networks. DEG-pathway network constructed by linking 153 DEGs (blue triangles), associated signaling pathways (yellow round rectangles), and cellular processes (green ellipses).](fphar-11-01174-g003){#f3}

###### 

Genes altered by ≥ 2× between the PAEs intervention and NS groups according to the enrichment results.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       GeneSymbol   Definition                                                                                  Graphic Symbol in [**Figure 3D**](#f3){ref-type="fig"}   Number   Map ID //Map name
  ---- ------------ ------------------------------------------------------------------------------------------- -------------------------------------------------------- -------- ------------------------------
  1    Adcy2        adenylate cyclase 2 \[EC:4.6.1.1\]                                                          ![](fphar-11-01174-g005.jpg)                             26       ko04151\
                                                                                                                                                                                  //PI3K-Akt signaling pathway

  2    Adcy3        adenylate cyclase 3 \[EC:4.6.1.1\]                                                                                                                            

  3    Akt3         RAC serine/threonine-protein kinase \[EC:2.7.11.1\]                                                                                                           

  4    Bmpr1b       bone morphogenetic protein receptor type-1B \[EC:2.7.11.30\]                                                                                                  

  5    Bub1         checkpoint serine/threonine-protein kinase \[EC:2.7.11.1\]                                                                                                    

  6    Camk2a       calcium/calmodulin-dependent protein kinase (CaM kinase) II \[EC:2.7.11.17\]                                                                                  

  7    Ccnb1        G2/mitotic-specific cyclin-B1                                                                                                                                 

  8    Cd36         CD36 antigen                                                                                                                                                  

  9    Cdc14a       cell division cycle 14 \[EC:3.1.3.16 3.1.3.48\]                                                                                                               

  10   Cdc25b       M-phase inducer phosphatase 2 \[EC:3.1.3.48\]                                                                                                                 

  11   Cdc25c       M-phase inducer phosphatase 3 \[EC:3.1.3.48\]                                               ![](fphar-11-01174-g006.jpg)                             20       ko04010\
                                                                                                                                                                                  //MAPK signaling pathway

  12   Cidea        DNA fragmentation factor, 45 kD, alpha subunit                                                                                                                

  13   Cidec        DNA fragmentation factor, 45 kD, alpha subunit                                                                                                                

  14   Ctsk         cathepsin K \[EC:3.4.22.38\]                                                                                                                                  

  15   Dbf4         activator of S phase kinase                                                                                                                                   

  16   Ddit4l       DNA-damage-inducible transcript 4                                                                                                                             

  17   Dpt          Notch 1                                                                                                                                                       

  18   Egf          epidermal growth factor                                                                                                                                       

  19   Fgf13        fibroblast growth factor                                                                    ![](fphar-11-01174-g007.jpg)                             13       ko04371\
                                                                                                                                                                                  //Apelin signaling pathway

  20   Fgf7         fibroblast growth factor                                                                                                                                      

  21   Flnc         filamin                                                                                                                                                       

  22   Flt1         FMS-like tyrosine kinase 1 \[EC:2.7.10.1\]                                                                                                                    

  23   Fos          proto-oncogene protein c-fos                                                                                                                                  

  24   Fzd2         frizzled 2                                                                                                                                                    

  25   Fzd9         frizzled 9/10                                                                                                                                                 

  26   Fzd10        frizzled 9/10                                                                               ![](fphar-11-01174-g008.jpg)                             12       ko04310\
                                                                                                                                                                                  //Wnt signaling pathway

  27   Grm1         metabotropic glutamate receptor 1                                                                                                                             

  28   Hspa1l       heat shock 70 kDa protein 1/2/6/8                                                                                                                             

  29   Igf1r        insulin-like growth factor 1 receptor \[EC:2.7.10.1\]                                                                                                         

  30   Itga7        integrin alpha 7                                                                                                                                              

  31   Itga11       integrin alpha 11                                                                                                                                             

  32   Itgb6        integrin beta 6                                                                                                                                               

  33   Itgbl1       tenascin                                                                                    ![](fphar-11-01174-g009.jpg)                             11       ko04068\
                                                                                                                                                                                  //FoxO signaling pathway

  34   Lama2        laminin, alpha 1/2                                                                                                                                            

  35   Lama4        laminin, alpha 4                                                                                                                                              

  36   Lamb2        laminin, beta 2                                                                                                                                               

  37   Lrrc2        erbb2-interacting protein                                                                                                                                     

  38   Map3k7cl     mitogen-activated protein kinase kinase kinase 7 \[EC:2.7.11.25\]                                                                                             

  39   Mapk12       p38 MAP kinase \[EC:2.7.11.24\]                                                             ![](fphar-11-01174-g010.jpg)                             12       ko04150\
                                                                                                                                                                                  //mTOR signaling pathway

  40   Myl2         myosin regulatory light chain 2                                                                                                                               

  41   Mylk2        myosin-light-chain kinase \[EC:2.7.11.18\]                                                                                                                    

  42   Mylk4        myosin-light-chain kinase \[EC:2.7.11.18\]                                                                                                                    

  43   Napb         alpha-soluble NSF attachment protein                                                                                                                          

  44   Nexn         myosin-light-chain kinase \[EC:2.7.11.18\]                                                                                                                    

  45   Nfatc2       nuclear factor of activated T-cells, cytoplasmic 2                                          ![](fphar-11-01174-g011.jpg)                             15       ko04014\
                                                                                                                                                                                  //Ras signaling pathway

  46   Nfatc4       nuclear factor of activated T-cells, cytoplasmic 4                                                                                                            

  47   Nlrc3        NACHT, LRR, and PYD domains-containing protein 3                                                                                                              

  48   Nos1         nitric-oxide synthase, brain \[EC:1.14.13.39\]                                                                                                                

  49   Pdgfb        platelet-derived growth factor subunit B                                                                                                                      

  50   Pdgfrl       kinase insert domain protein receptor \[EC:2.7.10.1\]                                                                                                         

  51   Peg10        poly \[ADP-ribose\] polymerase \[EC:2.4.2.30\]                                                                                                                

  52   Pgf          placenta growth factor                                                                      ![](fphar-11-01174-g012.jpg)                             7        ko04370\
                                                                                                                                                                                  //VEGF signaling pathway

  53   Pik3r6       phosphoinositide-3-kinase regulatory subunit alpha/beta/delta                                                                                                 

  54   Pla2g4e      cytosolic phospholipase A2 \[EC:3.1.1.4\]                                                                                                                     

  55   Plcb4        phosphatidylinositol phospholipase C, beta \[EC:3.1.4.11\]                                                                                                    

  56   Pm20d2       translation initiation factor 2 subunit 3                                                                                                                     

  57   Prkab2       5'-AMP-activated protein kinase, regulatory beta subunit                                    ![](fphar-11-01174-g013.jpg)                             8        ko04012\
                                                                                                                                                                                  //ErbB signaling pathway

  58   Prkag3       5'-AMP-activated protein kinase, regulatory gamma subunit                                                                                                     

  59   Pvalb        atrophin-1 interacting protein 1                                                                                                                              

  60   Pygm         glycogen phosphorylase \[EC:2.4.1.1\]                                                                                                                         

  61   Pygo1        SHC-transforming protein 1                                                                                                                                    

  62   Rasgrf1      Ras-specific guanine nucleotide- releasing factor 1                                         ![](fphar-11-01174-g014.jpg)                             9        ko04390\
                                                                                                                                                                                  //Hippo signaling pathway

  63   Rps6ka2      ribosomal protein S6 kinase alpha-1/2/3/6 \[EC:2.7.11.1\]                                                                                                     

  64   Rragd        Ras-related GTP-binding protein C/D                                                                                                                           

  65   Shc2         SHC-transforming protein 2                                                                                                                                    

  66   Slc25a31     solute carrier family 25 (mitochondrial adenine nucleotide translocator), member 4/5/6/31                                                                     

  67   Slc25a4      solute carrier family 25 (mitochondrial adenine nucleotide translocator), member 4/5/6/31   ![](fphar-11-01174-g015.jpg)                             7        ko04152\
                                                                                                                                                                                  //AMPK signaling pathway

  68   Stac3        signal transducing adaptor molecule                                                                                                                           

  69   Tgfb3        transforming growth factor beta-3                                                                                                                             

  70   Thbs2        thrombospondin 2/3/4/5                                                                      ![](fphar-11-01174-g016.jpg)                             8        ko04110\
                                                                                                                                                                                  //Cell cycle

  71   Thbs3        thrombospondin 2/3/4/5                                                                                                                                        

  72   Thbs4        thrombospondin 2/3/4/5                                                                                                                                        

  73   Tnxb         tenascin                                                                                                                                                      

  74   Ttc9         peptidyl-prolyl isomerase D \[EC:5.2.1.8\]                                                                                                                    

  75   Ttk          serine/threonine-protein kinase TTK/MPS1 \[EC:2.7.12.1\]                                    ![](fphar-11-01174-g017.jpg)                             9        ko04210\
                                                                                                                                                                                  //Apoptosis

  76   Vit          collagen, type VI, alpha                                                                                                                                      

  77   Wnt9a        wingless-type MMTV integration site family, member 9                                                                                                          

  78   Wnt11        wingless-type MMTV integration site family, member 11                                                                                                         

  79   Xirp1        methyl CpG binding protein 2                                                                ![](fphar-11-01174-g018.jpg)                             10       ko04217\
                                                                                                                                                                                  //Necroptosis

  80   Zcchc5       poly \[ADP-ribose\] polymerase \[EC:2.4.2.30\]                                                                                                                

  81   3632451\     high mobility group protein B1                                                                                                                                
       O06Rik                                                                                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#s4}
==========

*Periplaneta americana* (PA) is a common source of animal medicine that has a long history of use in TCM for the treatment of wounds and burns ([@B2]; [@B55]). Over the past two decades, PAEs have been tested for the promotion of gastric and duodenal ulcer healing ([@B27]), treatment of hepatic fibrosis ([@B20]), inhibition of tumor growth ([@B53]), stimulation of skin wound healing ([@B48]; [@B40]), and induction of skin fibroblast migration ([@B23]). The active constituents in PAEs with wound healing efficacy have been screened ([@B21]). The abovementioned studies, however, did not provide evidence for the healing potential of PAEs. To the best of our knowledge, the present study is the first to report on the liver regeneration efficacy of PAEs involving the synergy of multiple signaling pathways.

The present results have shown that PAEs promote hepatocyte proliferation both *in vitro* and *in vivo* and accelerate mouse liver regeneration after 70% partial hepatectomy. That PAEs can accelerate liver regeneration by affecting hepatocyte proliferation is evident by the increase in incidence of Ki-67 immunohistochemical stained hepatocyte nuclei. The DEGs bioinformatics analysis revealed that PAEs influence the expression levels of different genes after PH. On closer analysis, some of the DEGs participated in cellular processes and signaling pathways associated with cell growth or death. The cellular processes included cell cycle, apoptosis, and necroptosis. The signaling pathways included PI3K-Akt, MAPK, Apelin, Wnt, FoxO, mTOR, Ras, VEGF, ErbB, Hippo, and AMPK ([**Figure 3E**](#f3){ref-type="fig"}).

The murine 70% PH model is not associated with tissue injury or inflammation because the liver lobes are removed intact. Of note, the expression levels of the DEGs related to cell death were lower in the PAEs groups than the NS group. It stands to reason therefore that PAEs may protect hepatocytes by inhibiting cell death after liver injury. They may promote post-PH liver regeneration by inducing the proliferation of existing mature hepatocytes without activating the progenitor cells ([@B32]). Though the PAEs accelerated liver regeneration, the expression levels of the DEGs related to cell growth were lower in the PAEs group than the NS group. It is suggested that they may be concerned more with the process of liver regeneration after 70% PH.

After 70% PH, most of the hepatocytes in the residual lobes undergo one or two proliferative processes ([@B34]). In rats, the first peak in hepatocyte DNA replication occurs after \~24 h. A second smaller peak is observed between 36--48 h and there is a maximum rate of cell division at 36 h after PH. In contrast, there is species variation in peak DNA replication following PH; in mice, the peak was 12‑16 h later compared to rats ([@B32]). [@B37] suggested that for studies on the progression phase, the mice should be sacrificed at 36 (S-phase onset), 40, 48 (peak of DNA synthesis), and 60 h (termination of cell cycle activity) after PH. Here, we collected the liver samples at 48 h after liver resection. A peak in DNA replication and significant upregulation of the DEGs related to cell growth occurred in NS at this time point. There were comparatively higher HRR and relatively lower expression levels of the DEGs associated with cell cycle and proliferation in the PAEs groups. Hence, PAEs accelerate the initial hepatocyte proliferation process and hasten the arrival of the cells to the second proliferative event. PAEs improved L02 cell proliferation *in vitro;* thus, they possess liver regeneration potential.

Previous studies had explored the effects of single factors and pathways on liver regeneration. However, more recent reports demonstrated that numerous signaling pathways are involved in this process and their interactions are complex. [@B9] found that ALR (augmenter of liver regeneration, a protein that was identified to specifically support liver regeneration) induced miRNA-26a expression, upregulated the p-Akt/cyclin D1 pathway, and promoted hepatic cell proliferation. [@B14] found that EGR-1 (early growth response 1 gene)-induced GGPPS plays an important role in post-PH liver regeneration *via* RAS/MAPK signaling. [@B49] reported that Diwu Yanggan capsules can improve the liver regeneration microenvironment by regulating the Ras/Raf/Mek/Erk signaling pathway and regeneration-related factors. It has been reported in knockout mice or use of inhibitors that single-pathway disruption does not block but causes delay in regeneration. This suggests that a complex pathway network is vital for optimal liver regeneration and the generation of adequate hepatic mass ([@B35]; [@B32]). In an IL-6^-/-^ mouse model, liver regeneration was delayed ([@B6]). Gene expression and hepatocyte proliferation can be corrected with a preoperative IL-6 injection. After PH, Tnfr1^-/-^ mice presented with multiple liver regeneration defects whereas Tnf^-/-^ mice underwent normal liver regeneration. Thus, other ligands may bind to TNFr1 ([@B47]; [@B10]). In practice, pathophysiological processes are seldom induced by isolated changes in single molecular effectors. Indeed, physiological and pathological modulations are nearly always the result of the complex interactions of multiple signaling pathways.

PAEs are prepared from *Periplaneta americana* and contain various biologically active ingredients including polysaccharides, peptides, nucleosides, polyols, steroids, terpenes, alkaloids, flavonoids, and isocoumarins. The effective constituents may be attributed to polysaccharides, peptides, nucleosides, among others ([@B30]; [@B24]). Therefore, PAEs may have multiple molecular targets and biochemical properties. In our study, the main ingredients of PAEs are sticky sugar amino acid, based on the patent ([@B18]) involving Ganlong capsule; however, they are still not considered a natural pure compound drug. The efficacy of PAEs at accelerating liver regeneration after 70% PH was mediated by the synergistic effect of numerous targets and pathways associated with cell growth and death. These pathways can form complex interconnecting networks. In fact, certain DEGs participated in ≥ 2 pathways ([**Figure 4**](#f4){ref-type="fig"}). This discovery corroborates the synergy of action theory of multicomponent therapeutics TCM postulated by [@B29]. In the latter, the gene expression profiles of four active constituents in Danshen were analyzed. In this connection, molecular analysis of the expressions of the key signaling members by qPCR and western-blotting using L02 cells culture *in vitro* along with animal experimentation is clearly desirable. This would help unravel the major pathways and explore the mechanism that guide the enhancement of liver regeneration by the active ingredients of PAEs.

![PAEs accelerate liver regeneration *via* a complex network after 70% PH in mice.](fphar-11-01174-g004){#f4}

Though the liver can recover following hepatectomy, liver failure will nonetheless occur if the tissue loss is very extensive. This response is known as the Small-for-Size-Syndrome (SFSS). [@B44] reported that deficient liver regeneration is the principal cause of SFSS. Successful regeneration may lead to recovery from acute liver failure. However, no regenerative strategies for existing acute liver failure have been established ([@B13]). It is unequivocal from the present results that PAEs administered prior to surgery could enhance the postoperative liver regeneration capacity. Hence, PAEs might have clinical potential for the treatment of post-hepatectomy liver failure.

The previous study in mice showed that the toxicity grade of *Periplaneta Americana* was practically non-toxic ([@B54]). In our liver regeneration experiment, the mortality rate was \<10%. The main cause of death was bleeding caused by ligation line falling off after 70% PH. Abnormal manifestations were not observed in mice who were administered PAEs. Based on the BSA normalization method ([@B38]), human equivalent dose of PAEs (about 3.9 g/d), which was converted from the high dose (800 mg/kg) of mice, was less than 1/4 of the safe dose (18 g/d) ([@B18]). In the experiment, the doses of PAEs used were safe and effective. This indicates that PAEs are safe and indeed have the potential for clinical application.

Conclusions {#s5}
===========

To the best of our knowledge, the present study is the first to demonstrate that preoperative PAEs gavage increased postoperative liver regeneration capacity in mice. In the present liver regeneration experiment, the doses of PAEs used were safe and effective. This indicates that PAEs are safe and indeed have the potential for clinical application. More importantly, we show here that PAEs improved liver regeneration *via* a complex network of targets and signaling pathways. Though the present therapeutic approach using PAEs has practical merit, significance, and potential, the molecular targets, active constituents, and modes of action have not yet been elucidated. This will certainly be the scope of our future study.
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###### 

HPLC quantitative analysis. **(A)** HPLC chromatograms of mixed standard substances. **(B)** HPLC chromatograms of PAEs samples. **(C)** The merge of A and B. Peaks 1∼6 are derived from cytosine, uracil, cytidine, uridine, inosine, and guanosine, respectively. Two unknown substances were found in our study.
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Click here for additional data file.

###### 

The toxicity profile of the PAEs *in vitro*. **(A)** Representative images of CCK-8 color reactions in 96-well plates at 24 and 48 h after treatment with different PAEs concentrations (in Gibco RPMI 1640 Medium without HEPES and supplemented with 10% FBS). **(B)** PAEs at low dose (1 mg/ml) was found to accelerate moderate L02 cell proliferation. On the other hand, virtually all cells were killed by PAEs at high doses (25 or 50 mg/ml).
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Click here for additional data file.
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